Red cell aplasia in children on tacrolimus after liver transplantation

Transplantation

Volumn 65, Issue 4, 1998, Pages 575-577

  Misra, Sudipta ^a,d   Moore, Theodore B ^b   Ament, Marvin E ^c   Busuttil, Ronald W ^c   McDiarmid, Sue V ^a,c  

^a UCLA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Maimonides Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHILD; ERYTHROCYTE APLASIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; BLOOD TRANSFUSION; BONE MARROW; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; RED-CELL APLASIA, PURE; TACROLIMUS; TIME FACTORS;

EID: 0032570749     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199802270-00021     Document Type: Article

References (7)

1. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus, a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746.
2. Suzuki S, Osaka Y, Nakai I, et al. Pure red cell aplasia induced by FK 506. Transplantation 1996; 61: 831.
3. Jacobs P. Bone marrow failure: pathophysiology and management. Dis Month 1995; 41: 201.
4. Cherrick I, Karayalcin G, Lanzkowsky P. Transient erythroblastopenia of childhood: prospective study of fifty patients. Am J Pediatr Hematol Oncol 1994; 16: 320.
5. Hirao A, Kawano Y, Takaue Y. Effect of immunosuppressants, FK 506, deoxyspergualin and cyclosporine A on immature human hematopoiesis. Blood 1993; 81: 79.
6. Zhu X, Imamura M, Hashimo S, et al. Enhancing and suppressive effects of immunosuppressants cyclosporine A, FK 506 and KM2210 on the colony formation of murine bone marrow cells. Ann Hematol 1995; 71: 301.
7. Cooper MH, Patrene KD, Vechhini F, Austin CA, Markus PM, Boggs SS. Short term myeloid reconstitution following TBI is not adversely affected by doses of FK 506 that aborgate lethal GVHD. Bone Marrow Transplant 1994; 14: 355.